Zydus Launches REVAHALE as India's First Once-Daily Nebulised LAMA for COPD

Clearing CDSCO approval for a nebulised long-acting muscarinic antagonist formulation is not a routine exercise, and Zydus's commercial launch of REVAHALE signals that the company has navigated both the regulatory and manufacturing complexity that inhalation drug-device combinations demand in India. REVAHALE is positioned as the country's first and only LAMA combining once-daily dosing with nebulised delivery for COPD patients.

Inhalation products occupy a technically demanding tier within GMP compliance. Formulation stability, aerosol particle-size distribution, and container-closure integrity each carry distinct validation obligations under 21 CFR Part 211 equivalents and ICH Q10 quality system expectations. For a nebulised solution, sterility assurance and extractables-leachables profiling from the device components add further layers that QA teams must document before a product reaches commercial release.

The device-drug combination classification also shapes the regulatory pathway. Where the nebuliser and the drug solution are co-developed or co-labelled, CDSCO's review scope can extend beyond the active pharmaceutical ingredient to encompass device performance data, a requirement that lengthens dossier preparation and demands cross-functional alignment between formulation, regulatory affairs, and device engineering teams.

From a market-access standpoint, once-daily nebulised dosing addresses a specific patient segment: those with moderate-to-severe COPD who cannot reliably coordinate dry-powder or pressurised metered-dose inhalers. Expanding the nebulised LAMA category in India also creates a reference point for future lifecycle management filings, including combination products that pair a LAMA with a long-acting beta-agonist in the same nebulised format.

Process validation documentation for the REVAHALE manufacturing line will serve as a benchmark for any competitor seeking to enter the nebulised LAMA space in India, given the absence of a prior approved product against which CDSCO reviewers could calibrate expectations.

Source: Media4Growth via Indian Pharma Post, 9 August 2026.